Both micropulse photocoagulation, half-dose PDT may treat central serous chorioretinopathy

Issue: January 10, 2016

Both micropulse photocoagulation and half-dose verteporfin photodynamic therapy may reduce leakage, resolve subretinal fluid and increase visual acuity in the treatment of central serous chorioretinopathy, according to a study.

The comparative, prospective clinical trial evaluated 62 central serous chorioretinopathy patients, randomizing 20 eyes to be treated with subthreshold diode laser micropulse therapy (Iridex), 24 eyes to be treated with half-dose Visudyne (verteporfin, Bausch + Lomb) PDT and 18 eyes to serve as controls.

Leakage on fluorescein angiography improved significantly in both treatment groups, with 60% of eyes in the micropulse group and 66.7% of eyes in the PDT group showing no persistent leakage at 16 weeks, while only 33.3% of eyes in the control group had a significant decrease in leakage activity.

Best corrected visual acuity improved from 86.9 ± 14.3 at baseline to 93.6 ± 10.9 at 16 weeks in the micropulse group and from 82.8 ± 11.5 at baseline to 91.3 ± 13.8 at 16 weeks in the PDT group, while the control group only improved from 96.4 ± 8.8 at baseline to 97.9 ± 10.7 at the final follow-up.

After therapy, no significant retinal pigment epithelium changes were detected with fundus autofluorescence.

Central macular thickness decreased by 69.7 µm in the micropulse group, 109.8 µm in the PDT group and 89 µm in the control group. – by Kristie L. Kahl

Disclosure: The authors report no relevant financial disclosures.

Published by:

Sources/Disclosures

Collapse

Source:

Kretz FTA, et al. Ophthalmic Surg Lasers Imaging Retina. 2015;doi:10.3928/23258160-20150909-08.